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Abstract
Master regulator protein p53, popularly known as the ‘‘guardian of genome’’ is the hub for regulation of diverse cellular
pathways. Depending on the cell type and severity of DNA damage, p53 protein mediates cell cycle arrest or apoptosis,
besides activating DNA repair, which is apparently achieved by regulation of its target genes, as well as direct interaction
with other proteins. p53 is known to repress target genes via multiple mechanisms one of which is via recruitment of
chromatin remodelling Sin3/HDAC1/2 complex. Sin3 proteins (Sin3A and Sin3B) regulate gene expression at the chromatin-
level by serving as an anchor onto which the core Sin3/HDAC complex is assembled. The Sin3/HDAC co-repressor complex
can be recruited by a large number of DNA-binding transcription factors. Sin3A has been closely linked to p53 while Sin3B is
considered to be a close associate of E2Fs. The theme of this study was to establish the role of Sin3B in p53-mediated gene
repression. We demonstrate a direct protein-protein interaction between human p53 and Sin3B (hSin3B). Amino acids 1–
399 of hSin3B protein are involved in its interaction with N-terminal region (amino acids 1–108) of p53. Genotoxic stress
induced by Adriamycin treatment increases the levels of hSin3B that is recruited to the promoters of p53-target genes
(HSPA8, MAD1 and CRYZ). More importantly recruitment of hSin3B and repression of the three p53-target promoters upon
Adriamycin treatment were observed only in p53
+/+ cell lines. Additionally an increased tri-methylation of the H3K9 residue
at the promoters of HSPA8 and CRYZ was also observed following Adriamycin treatment. The present study highlights for
the first time the essential role of Sin3B as an important associate of p53 in mediating the cellular responses to stress and in
the transcriptional repression of genes encoding for heat shock proteins or proteins involved in regulation of cell cycle and
apoptosis.
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Introduction
The p53 gene is widely recognized as the master regulator of
diverse cellular networks. p53 is a sequence specific transcription
factor capable of transactivation and transrepression [1–3].
Although the mechanisms of p53 mediated gene activation are
extensively analyzed (reviewed in ref. [4]), bonafide transcription
repression by p53 had initially received less attention. The last
decade, however, has witnessed identification of principally three
mechanisms for repression of a repertoire of p53 target genes:
competition with transcription activator for DNA binding,
sequestration of transcription activators or recruitment of co-
repressor/chromatin-modifying factors (reviewed in ref. [5]).
Recruitment of co-repressor complex like Sin3/HDAC complex
by DNA binding transcription factor is an evolutionary conserved
mechanism of transrepression. Sin3 has been established as a
master transcriptional scaffold and co-repressor capable of
transcriptional silencing via associated HDACs. In 1999, Murphy
and co-workers reported that p53 interacts with mSin3A and
negatively regulates two cytoskeletal genes: Map4 and Stathmin [6].
Subsequently various p53 responsive genes like Mad1, HSP90b and
Nanog have been reported to be repressed by p53 via recruitment
of Sin3A/HDAC complex to the p53 response element [7–9]. In
mammals two highly homologous isoforms, Sin3A and Sin3B have
been reported [10]. However the functional redundancy and/or
specificity of Sin3A and Sin3B are poorly understood (reviewed in
ref. [11]). Several studies implicate that these two proteins target
similar subset of genes while other reports highlight a clear
functional demarcation between the two proteins. At the level of
protein-protein interaction MAD1, KLF, REST, ESET interact
with both the isoforms while proteins like SMRT and MeCP2
appear to bind specifically to Sin3A [12–14]. On the other hand,
CIITA mediates its transrepression functions via exclusively
recruiting the Sin3B/HDAC2 complex [15]. Sin3A is involved
in mediating p53 dependent gene repression [6,8], while Sin3B/
HDAC co-repressor complex is recognized to be an essential
regulator of chromatin modification at the E2F-target promoters
([16], reviewed in ref. [17]). The existence of such functional
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investigate whether p53 utilizes Sin3B/HDAC co-repressor for
mediating its transrepression function at subset of its target
promoters. We demonstrate recruitment of the human Sin3B/
HDAC1 complex at three of the p53-repressed target promoters
accompanied by altered histone methylation and a concomitant
repression of these genes under conditions of genotoxic insult,
thereby highlighting for the first time, Sin3B as an important
player in p53-mediated gene repression.
Results
Human p53 co-immunoprecipitates phosphorylated
human Sin3B
To investigate the role of human Sin3B (hSin3B) in p53 trans-
repression functions, we initially performed co-immunoprecipita-
tion assays to test the association between p53 and hSin3B in three
different human cell lines. Total cell lysates from wild-type p53
+/+
cell lines (KB, HCT116 and HEK293) were immunoprecipitated
with anti-p53 antibody and the immunoprecipitates were probed
for the presence of hSin3B by immunoblot analysis. As shown in
figure 1 hSin3B was recovered in the p53 immunoprecipitates in
p53
+/+ cells but not in either the mock immunoprecipitation or the
p53-null cell line, Saos2. Keeping in mind the high degree of
homology between Sin3A and Sin3B, the identity of the 130 kD
band of hSin3B was further examined by western analysis using
antibodies targeted against regions specific to Sin3B (antibodies sc-
768; sc-55516; sc-13145; Santa Cruz Biotechnology, USA).
Identical and reproducible results were obtained with all the three
immunoblot analysis suggesting that the 130 kD protein, co-
immunoprecipitated with p53, is indeed hSin3B (Figure 1 and
Supplementary Figure S1).
Reciprocal IP-Western experiments in KB cells demonstrated
that hSin3B could also co-immunoprecipitate p53 protein (53 kD),
reaffirming that hSin3B interacts with p53 in vivo (Figure 1D).
Sin3B has potential sites for several post translational modifica-
tions like myristoylation and phosphorylations (reviewed in ref.
[11]). The phosphorylation status of p53-bound Sin3B was
analyzed by immunoblotting p53 immune complexes with
antibodies targeted against phosphorylated serine, threonine and
tyrosine. Appearance of a phosphorylated 130 kD protein band
juxtaposed to the hSin3B protein (Figure 1A), observed with all the
three antibodies, suggested that hSin3B interacting with p53 is
indeed phosphorylated. However, whether phosphorylation is
crucial for this interaction and the role of phosphorylation, if any,
in mediating p53-Sin3B functions remain to be elucidated.
Our studies show that hSin3B co-immunoprecipitates with
HDAC1 in a p53-independent manner (see Supplementary Figure
S2). This is consistent with the previous reports showing that
Sin3B mediates the trans-repression function of various DNA-
binding transcription factors via interaction with HDAC1/2
[16,18,19]. Taken together these results suggest that p53 can
utilize Sin3B/HDAC1 complex for its transrepression functions.
Paired Amphipathic Helices (PAH) 1–3 domains of hSin3B
are crucial for direct protein-protein interaction with
human p53
To confirm direct protein-protein interaction between hSin3B
and human p53 (hp53), yeast two hybrid assays were performed.
Each of the three overlapping fragments spanning full length
coding sequence of hSin3B were fused to the GAL4 DNA
binding domain and were used as bait (Supplementary Figure
S3). Human p53 was fused with GAL4 activation domain and
was used as prey. All the yeast two hybrid specificity controls did
not autonomously activate the reporter genes. AH109 cells of
Saccharomyces cerevisiae co-transformed with pGBKT7-p53 (murine
p53) and pGADT7-T (Large T antigen) were used as positive
control. AH109 cells, co-transformed with hp53 and hSin3B 1–399
(spanning PAH 1–3 domains of hSin3B) or hSin3B 193–468
Figure 1. Phosphorylated hSin3B associates with hp53 in vivo. (A & B) Cell lysates from KB, HEK293 (A) and HCT116 cell lines (B) were
immunoprecipitated (IP) with antibody specific for p53 followed by immunoblot analysis (IB) with antibodies specific for hSin3B (sc-13145 for KB and
HCT116 cell lines; sc-55516 for HEK293 cells), phosphorylated serine (anti-pSer), phosphorylated tyrosine (anti-pTyr), phosphorylated threonine (anti-
pThr) as indicated above each lane. Western analysis indicates the co-immunoprecipitation of phosphorylated hSin3B with p53 in KB, HEK293 and
HCT116 cell extracts. (C) IP-Western analysis in p53-null cell line (Saos2) shows that hSin3B was detectable only in the input lane but not in the
immune complex obtained from antibody against p53 or in the mock immunoprecipitates. (D) Reciprocal IP-Western analysis in KB cell extract using
the ImmunoCruz
TM IP/WB Optima E System (Santa Cruz) as described in the methods section reveals the presence of p53 in a complex with hSin3B. In
all the experiments input corresponds to 10% of the total cell lysate used for each immunoprecipitation.
doi:10.1371/journal.pone.0026156.g001
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blue colonies on quadruple drop-out medium with X-gal (QDO-
Xgal; Figure 2A and B), whereas cells co-transformed with hp53
and pGBKT7-Sin3B442–1162 or vector alone did not grow on
QDO-Xgal plates suggesting that Sin3B 442–1162 (spanning HID,
PAH4 and HCR domain of hSin3B; Supplementary Figure S3)
was not capable of interaction with hp53. The lack of growth on
selection medium was not due to lack of expression of hSin3B442–
1162 as all the clones of hSin3B expressed at detectable levels
(Supplementary Figure S4). Three additional truncated hSin3B
constructs (Sin3B1–247, Sin3B1–179, Sin3B168–399; Figure 2C) were
co-transformed in AH109 cells with pGADT7-p53 to discreetly
identify the PAH domains crucial for interaction with hp53.
Yeast two hybrid results indicated that only Sin3B168–399 interacts
with hp53 (Figure 2C). Closer examination of the three hSin3B
constructs that gave positive interaction with p53 in yeast two
hybrid assays, show that the overlapping amino acids between the
three constructs are amino acids 193–399. This region of hSin3B
Figure 2. Yeast two Hybrid analysis for the interaction of hSin3B with hp53. (A) & (B) Yeast AH109 cells were co-transformed with plasmids
indicated below the plates for each sector. Successful co-transformations were confirmed by growth on SD LT plates (Drop-out medium lacking
Leucine and tryptophan). The protein-protein interactions were checked by growing the co-transformants on selective SD QDO-Xgal medium
(Quadruple drop-out medium lacking leucine, tryptophan, adenine and histidine and containing X-gal). Positive interaction was observed only
between pGBKT7-Sin3B1–399 and pGADT7-hp53 (Figure 2A, sector A) as well as pGBKT7-Sin3B193–468 and pGADT7-hp53 (Figure 2B, Sector A). (C)
Schematic representation of the various truncated forms of hSin3B used in the yeast two hybrid assays. Each truncated Sin3B construct was co-
tranformed with hp53 in AH109 cells and interaction was checked by observing growth on selective medium (SD QDO-Xgal). A plus sign (+) indicates
positive interaction and negative sign (2) indicates no interaction. (D) b-galactosidase assays were performed to quantify two-hybrid interactions. A
9.961.813 fold increase in the relative b-galactosidase units was observed for hp53/Sin3B1–399 interactions while a 1.960.107 fold increase was
observed for hp53/Sin3B193–468 interaction. All values are plotted with 6SEM calculated for three independent experiments. (E) Yeast AH109 cells
were co-transformed with plasmids indicated below the plates for each sector. Positive interaction was observed between pGBKT7-Sin3B1–399 and
pGADT7-hp531–108 (sector B) as indicated by growth on selective medium (SD QDO-Xgal).
doi:10.1371/journal.pone.0026156.g002
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(Figure 2C). However, b-galactosidase activity in the cell extracts
reveal that while the construct containing PAH 1–3 domains of
hSin3B gives a 9.961.813 fold increase in the relative b-
galactosidase activity, the Sin3B construct containing only PAH
2–3 domains shows a mere 1.960.107 fold increase for hp53-
Sin3B interaction (n=3 biological replicates; Figure 2D). These
observations strongly suggest that while amino acids 193–399 of
hSin3B are indispensable for interaction with hp53; the hSin3B
region containing the PAH 1 domain (amino acids 1–179) also
contributes significantly to the overall strength of interaction with
hp53 protein.
Sin3B interaction domain (SID) of p53 lies within N-
terminal 108 amino acids
In our initial yeast two hybrid assays, N-terminal deleted murine
p53 (mp53 lacking the 1–72 amino acids), failed to interact with
Sin3B (Supplementary Figure S5). These results and the fact that
mp53 is homologous to hp53 gave us a clue that like Sin3A [20],
Sin3B may also interact with the N-terminal region of p53. To
confirm this hypothesis amino acids 1–108 of hp53 were cloned in
pGADT7 and tested for interaction with hSin3B. As indicated in
figure 2E a positive interaction was observed, suggesting that the
Sin3 interaction domain (SID) of hp53 lies within N-terminal 108
amino acids.
Increased expression of hSin3B upon treatment with
Adriamycin: a DNA damaging agent
Various cellular stresses are known to increase the levels of p53
and trigger diverse regulatory response pathways. However, there
is little understanding of the regulation of levels and function of
hSin3B under similar conditions of cellular stress. One such report
by Grandinetti and co-workers shows an increase in the expression
of Sin3B upon oncogenic stress [21]. Since we observed an
interaction between p53 and hSin3B, we investigated the changes
in the RNA and protein levels of hSin3B upon treatment with
Adriamycin, a DNA damaging agent known to increases the levels
of p53 and elicit a p53 response [22–24]. Similar to previous
reports [25,26], we also observed Adriamycin induced cell-cycle
perturbation (one of the p53-regulated responses), wherein a
predominant G2 cell cycle arrest was evident in KB cell line while
a S/G2 arrest was observed in HCT116 cells (Figure 3A). Semi-
quantitative RT-PCR indicated a significant increase in the RNA
levels of both p53 and hSin3B post-adriamycin treatment
(Figure 3B). Immuno-staining using flow cytometry and western
blotting carried out under these conditions clearly show signifi-
cantly higher levels of p53 as well as hSin3B proteins (Figure 3C
and D). Increased expression of hSin3B, prompted us to
investigate whether Adriamycin treatment results in increased
interactions between p53 and hSin3B. Co-immunoprecipation
assays performed in cell lysates subsequent to Adriamycin
treatment show that while hSin3B and p53 interaction is
maintained under conditions of stress, the increased level of
hSin3B protein in cells does not lead to increased amounts of
Sin3B in the p53 immune complexes (Figure 3E). To investigate
whether this increase in Sin3B protein is a direct effect of DNA
damage induced by Adriamycin or downstream to p53 activation,
we analyzed Sin3B levels in p53 null cell lines Saos2, H1299 and
Hep3B. While Adriamycin treatment induced a predominant S/
G2 phase arrest in all the p53-null cell lines (Supplementary Figure
S6), no increase was observed in the RNA or protein levels of
Sin3B (Figure 3F).
P53 and Sin3B/HDAC1 are recruited on the promoters of
Heat shock protein 71 (HSPA8), Mitotic arrest deficient-
like 1 protein (MAD1) and Zeta crystallin (CRYZ)
p53 has been found to interact with transcriptional co-repressor
Sin3A in multiprotein complex which represses the transcription
of many genes [5,6]. To investigate the functional relevance of the
interaction between p53 and hSin3B proteins, we explored the
interactions of these two proteins with endogenous p53-responsive
promoters by ChIP assays using antibodies specific for p53, Sin3B,
HDAC1 in KB and HCT116 cell lines (Figure 4). A consistent
recruitment of hSin3B was observed at three p53-repressed
promoters and significantly high levels of endogenous HSPA8,
MAD1 and CRYZ promoters were detected in ChIP analysis in
contrast to mock immunoprecipitates, both before and after
Adriamycin treatment (Figure 4B and C). Sin3B-immunoprecip-
itates from p53-null cells (Saos2 and Hep3B) either did not contain
any detectable amount of chromatin or had chromatin equivalent
to mock immunoprecipitates (no antibody controls), suggesting no
significant association with target promoters (Figure 4D). This
suggests that recruitment of hSin3B to target promoters is p53-
dependent.
HSPA8, MAD1 and CRYZ promoters are transcriptionally
repressed upon treatment with Adriamycin
We next investigated the effect of Adriamycin treatment on the
mRNA levels of HSPA8, MAD1 and CRYZ genes. Levels of p21
transcript, a well-known p53-transactivated target, post-adriamy-
cin treatment were also tested. The drug induced a significant
reduction in the levels of HSPA8, MAD1 and CRYZ transcripts in
p53
+/+ KB and HCT116 cells (Figure 5A). Three independent
experiments (n=3) of quantitative PCR demonstrated a 2.76
0.1696 fold repression of HSPA8, 3.560.4561 fold reduction of
MAD1 and 2.360.1292 fold repression of CRYZ transcripts, while
a2 9 60.6124 fold activation of p21 transcript was evident in KB
cells. Similarly in HCT116 cells, 1.960.2496 fold repression was
observed for HSPA8 while a 5.061.456 fold and 1.560.1670 fold
repression was observed for MAD1 and CRYZ genes respectively
(Figure 5B and Supplementary Figure S7). Since we observed
differences in Sin3B recruitment at the p53-target promoters,
between p53
+/+ and p53
2/2 cells, we analyzed the HSPA8, MAD1
and CRYZ transcript levels in p53
2/2 cells as well. Although
Adriamycin treatment induced predominantly S phase arrest in
p53-null cells (Supplementary Figure S6), repression of these
promoters was not observed (Figure 5C). Since p53 functions are
known to be modulated in a cell-type specific manner (reviewed in
ref. [27]), we compared the HSPA8, MAD1 and CRYZ transcript
levels, post-adriamycin treatment, in two non-small cell lung
carcinoma cell lines viz. A549 (with wild-type p53 status) and
H1299 (p53-null cells). Similar to our observations in KB and
HCT116 cell lines, a significant repression of target genes was
observed upon Adriamycin treatment in A549 cell line, while no
change in the transcript levels was observed in H1299 cells
(Figure 5D). Taken together, these results indicate that a
ubiquitous p53-mediated recruitment of Sin3B-HDAC1 complex
is indispensable for repression of HSPA8, MAD1 and CRYZ
promoters.
H3K9 residue is hyper-methylated at HSPA8 and CRYZ
promoters post Adriamycin treatment
Since we found that p53-Sin3B are recruited at the target
promoters and bring about gene repression, we next examined the
epigenetic modifications at the promoter of HSPA8, MAD1 and
CRYZ before and after genotoxic insult. Methylation of H3 lysine 9
Recruitment of Human Sin3B at p53-Target Genes
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Adriamycin for 16 hours followed by propidium iodide staining and cell cycle analysis. Adriamycin treatment induced a predominant G2 cell cycle
arrest in KB cells and S/G2 arrest in HCT116 cells. (B) Total RNA was isolated and cDNA was synthesized from KB and HCT116 cells with or without
Adriamycin treatment. Semi-quantitative PCR results indicated increased levels of p53 and hSin3B mRNA levels in Adriamycin treated cells. (C) Upper
panel shows the results of immuno-fluorescence assays using flow cytometry. Lower panel is a plot of the above results comparing the mean
fluorescence intensity for p53 and hSin3B in the untreated and Adriamycin treated cells. A significant increase in p53 (P=0.0049 in KB and P=0.0036
in HCT116 cells) and hSin3B proteins (P=0.0234 in KB and P=0.0365 in HCT116 cells) was observed following Adriamycin treatment. The values have
been plotted with 6SEM calculated from three (n=3) independent experiments. (D) Western analysis of cell lysates of control and Adriamycin treated
KB cells showed an increase in the hSin3B and p53 protein levels upon treatment with 1.0 and 2.0 mg/ml Adriamycin. (E) IP-Western analysis of KB cell
extract after treatment with 1.0 mg/ml Adriamycin indicates the co-immunoprecipitations of hSin3B with p53 both before and after Adriamycin
treatment. (F) Results of semi-quantitative PCR (upper panel) and immuno-fluorescence assays using flow cytometry (lower panel) showed no
significant change in the expression levels of either hSin3B transcript or protein in p53-null cells viz. (i) Saos2 (ii) H1299 and (iii) Hep3B cells following
treatment with 1.0 mg/ml Adriamycin. In all the immuno-fluorescence experiments using flow cytometer (C & F) pink histograms represent cells not
treated with Adriamycin and Blue histogram represent Adriamycin treated cells. Black and green histograms represent the autofluorescence and
isotype controls respectively. For all the RT-PCR experiments 18S rRNA was used as endogenous control and for western blotting, expression of b-
actin was used as loading control. Representative results of three independent experimental sets are shown. In panel B and F ** indicates primer
dimers.
doi:10.1371/journal.pone.0026156.g003
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PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e26156Figure 4. Human p53 and Sin3B/HDAC1 complex associates in vivo with HSPA8, MAD1 and CRYZ promoters. (A) Schematic
representation of p53 response element and the amplified promoter region of HSPA8, MAD1 and CRYZ genes. The arrows indicate the position of the
respective Forward and Reverse primers used in the ChIP Assays. (B)–(D) ChIP assays in KB (B), HCT116 (C) and p53-null cells (D). Equal amounts of
cross-linked chromatin were pre-cleared and incubated with anti-p53 (sc-6243), anti-Sin3B (sc-768X) or anti-HDAC1 (sc-8410) as indicated above each
lane. Following DNA precipitation samples were analyzed by PCR using primers specific for HSPA8, MAD1, CRYZ promoters. For negative PCR control,
template was replaced with PCR-grade water. ** indicates primer dimers or non-specific amplification. Input corresponds to 10% of the total
chromatin used for each immunoprecipitation. Representative figure of four independent experiments.
doi:10.1371/journal.pone.0026156.g004
Recruitment of Human Sin3B at p53-Target Genes
PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e26156residue (H3K9) is one of the most well-characterized histone
modifications and is an epigenetic marker for trans-repression [28–
30]. We therefore analyzed the methylation at the H3K9 residue
at the respective promoters in the presence and absence of
Adriamycin treatment by ChIP analysis using antibodies specific
for trimethylated H3K9 residue (H3K9Me3). Adriamycin clearly
induced hyper-methylation of H3K9 at the promoters of p53
repressed genes, HSPA8 and CRYZ while p53-activated promoter,
p21 showed hypomethylation (Figure 6). However, we did not
observe any significant changes in the methylation of H3K9
residue at the MAD1 promoter.
Discussion
Genome wide expression analysis using micro-array has
suggested that p53 can repress several cellular promoters involved
in diverse pathways [3]. Some of the factors that may affect p53
transcription functions could be location of p53 binding site at the
target gene and/or its proximity with the binding site of other
activators or repressors, type of cellular stress and interaction with
cell-type specific trans-acting factors. Diverse mechanisms have
been proposed for p53 mediated repression of the target gene
expression. For instance, p53 represses the alpha-fetoprotein gene
expression by inhibiting the binding of hepatic nuclear factor3 on
the promoter, while trans-repression by p53 on human immediate
early response gene X-1 promoter is dependent on non-
competitive DNA binding between p53 and Sp1 to their sites
[31,32]. An association between p53 and evolutionary conserved
Sin3A co-repressor complex that lead to repression of cytoskeletal
genes Map4 and stathmin has also been demonstrated [6]. It is now
established that p53 negatively regulates several genes like Map4,
DNA topoisomerase IIa, bcl2, presenilin-1, Hsp90b, and survivin
(reviewed in ref. [5]), that has put p53 in the league of bonafide
transcription repressors.
In the present study we report for the first time utilization of
hSin3B by p53 for its trans-repression functions. While we
demonstrated a direct protein-protein interaction between p53-
Sin3B in situ using yeast two hybrid analysis and co-immunopre-
cipitation, we also identified the interaction domains of the two
proteins and provide evidence that the Sin3-interaction domain
(SID) of p53 lies within its N-terminal 108 amino acids (Figure 2E).
Interestingly, this region of p53 contains the proline rich domain,
which has been associated with p53 regulatory responses like
trans-repression and apoptosis [33–35]. Our findings also establish
that amino acids 193–399 of Sin3B are essential for interaction
with p53. The results of protein-protein interaction studies led us
to investigate the physiological relevance of p53-Sin3B interaction.
Since, p53 regulatory responses are elicited principally under
Figure 5. HSPA8, MAD1 and CRYZ promoters are repressed upon treatment with Adriamycin in p53
+/+ cells. (A & B) Total RNA was
isolated and cDNA was synthesized from p53
+/+ cell lines: KB & HCT116 with or without Adriamycin treatment. Semi-quantitative PCR results (A)
indicated an Adriamycin treatment induced transcriptional repression of HSPA8, MAD1 and CRYZ promoters and transcriptional activation of p21.
Quantitative RT-PCR (B) re-confirmed the repression of the three genes in both KB and HCT116 cell lines. The values have been plotted with 6SEM
calculated from three (n=3) independent experiments. (C) cDNA was synthesized from total RNA isolated from p53
2/2 cell lines: Hep3B and Saos2
cells with or without Adriamycin treatment followed by semi-quantitative PCR. No significant change in transcript levels of HSPA8, MAD1 and CRYZ
was observed in Hep3B and Saos2 cells. (D) cDNA was synthesized from total RNA isolated from two non-small cell lung carcinoma cell lines, A549
(p53
+/+) and H1299 (p53
2/2). No significant change in the expression was observed for the three genes in H1299 cells. In contrast a strong repression
of HSPA8, MAD1 and CRYZ was observed in A549 cells. For all expression studies 18S rRNA was used as endogenous control. Representative figures of
three independent experiments are shown. ** indicates primer dimers.
doi:10.1371/journal.pone.0026156.g005
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between these two proteins following exposure of cells to genotoxic
stress caused by Adriamycin which functions by DNA intercala-
tion and complex formation with topoisomerase II [22]. In
previous reports an increase in the p53-Sin3A immune complex
has been observed under conditions of cellular stress [6,36]. In
contrast our co-immunoprecipitation experiments did not show
any significant increase in the p53-Sin3B complex. Grandinetti
and co-workers have shown that levels of Sin3B are up-regulated
upon oncogenic stress [21]. Our data presented here, indicate that
the levels of Sin3B are also up-regulated upon genotoxic stress
induced by Adriamycin, emphasizing on the potential role of
Sin3B in DNA damage response pathways. Although Sin3B is
expressed in p53-null cell lines, the levels of Sin3B are not
modulated in these cell lines upon genotoxic stress, thus suggesting
that p53 may directly or indirectly regulate Sin3B expression
under conditions of stress (Figure 3F). This regulation can exist
both at the transcriptional and post-transcriptional level. Since the
promoter of Sin3B has not been identified, at present it cannot be
ascertained whether p53 regulates Sin3B at the transcriptional
level. Studying the post-transcriptional regulation of Sin3B
however, requires due attention.
To analyze the recruitment of Sin3B on p53-repressed
promoters, we initially screened a subset of p53-target genes that
are involved in cell cycle, apoptosis and DNA repair. Our ChIP
data suggested ubiquitous recruitment of Sin3B/HDAC1 on three
p53-repressed promoters viz HSPA8, MAD1 and CRYZ. Previous
studies have suggested a dynamic binding of p53 to its target sites
before and after stress/DNA damage [37–39]. Consistent with
these finding, we also show recruitment of p53 and Sin3B at the
p53-target sites both before and after Adriamycin treatment. ChIP
and RT-PCR assays in p53
+/+ and p53
2/2 cell lines indicate that
recruitment of hSin3B on HSPA8, MAD1 and CRYZ is p53-
dependent, and in the absence of p53 protein, no other DNA-
binding transcription factors can rescue the p53-mediated
repression of HSPA8, MAD1 and CRYZ subsequent to Adriamycin
treatment.
HSPA8 has been identified as a p53-repressed target; however
the mode of transcriptional repression by p53 was unclear [3].
Our results presented here clearly indicate a direct sequence-
specific binding of p53 to the HSPA8 promoter followed by p53-
dependent recruitment of Sin3B/HDAC1 co-repressor complex
as well as hyper-methylation of the H3K9 residue upon Adria-
mycin treatment. Hspa8 repression is critical for the functional
activation of p53 because Hspa8 protein is known to antagonize
the p53 nuclear localization by masking the NLS sequence of p53
[40].
Zeta crystallin has been shown to stabilize the mRNA of an
anti-apoptotic gene, bcl2 by binding to its unique AU rich elements
(AURE) in the 39 UTR of the mRNA [41]. In this study we
observed that repression of CRYZ was p53-dependent and
mediated through the recruitment of Sin3B/HDAC1 co-repressor
complex coupled with hyper-methylation of the H3K9 residue.
p53 is known to negatively regulate expression of bcl2 through a
pathway independent of Sin3/HDAC1 [42]. Our results here
suggest that p53 may down-regulate bcl2 expression by repression
of zeta crystallin; latter altering the stability of bcl2 mRNA. This
hypothesis is supported by the fact that trans-repression activity of
p53 is required for induction of apoptosis as mutants of p53 which
are incapable of inducing apoptosis are also defective in trans-
repression activity [43]. Furthermore, deletion of proline-rich
domain of p53 (a region important for interaction with hSin3B as
shown by us), causes loss of repression as well as induction of
apoptosis without affecting its trans-activation [33–35]. Based on
our studies we envisage that p53 may regulate apoptosis by
modifying bcl-2 expression using multiple pathways.
Figure 6. H3 Lysine 9 residue at the HSPA8 and CRYZ promoters is hyper-methylated upon Adriamycin treatment. KB cells with or
without Adriamycin treatment (1 mg/ml) for 16 hours were harvested. Equal amounts of cross-linked chromatin were pre-cleared and incubated with
anti-H3K9Me3 antibody. Following DNA precipitation samples were analyzed by PCR using primers specific for HSPA8, MAD1, CRYZ promoters. For
negative PCR control, template was replaced with PCR-grade water. Input corresponds to 10% of the total chromatin used for each
immunoprecipitaion. ** indicates primer dimers. Arrows indicate the desired amplicon.
doi:10.1371/journal.pone.0026156.g006
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important member of the Spindle Assembly Complex and was
shown to be repressed via chromatin remodeling induced by p53-
mediated recruitment of Sin3A/HDAC1 complex [7]. In the
present study we observed a strong repression of MAD1 expression
upon treatment with Adriamycin that was additionally associated
with the recruitment of hSin3B on p53 response element of the
MAD1 promoter. However, we did not observe H3K9 hyper-
methylation on the MAD1 promoter reflecting that the nature and
combination of the histone post-translational modifications may
not be same for all p53-repressed promoters. Possibly other
epigenetic markers like methylation at H3K27, H4K20, ubiqui-
tination or sumoylation may be directing the transcription at the
MAD1 promoter. Interestingly the p53 response element for
MAD1 gene is upstream of the transcription start site (TSS) while
that for HSPA8 and CRYZ is down-stream to the TSS (Figure 4A).
The functional significance of this observation, if any, with histone
methylation pattern is not clear at present.
The coordinated and dynamic regulation by specific Histone
lysine methyl transferases (HKMTs) and Histone lysine demethy-
lases (HKDMs) is an important epigenetic mechanism that plays a
vital role in eukaryotic gene expression [44]. In the present study
we establish an increased H3K9 trimethylation following Adria-
mycin treatment at the p53/Sin3B-repressed HSPA8 and CRYZ
promoters. H3K9 methylation is also associated with p53 me-
diated repression of alpha-fetoprotein via SnoN corepressor [45].
However the mechanisms dictating H3K9 methylation and the
ensuing gene repression still remain unclear. H3K9 methylation
provides the binding site for the HP-1 protein that participates in
silencing gene expression both in the euchromatin and hetero-
chromatin [46]. Recently it was suggested that Sin3B may co-
ordinate the recruitment of HKMT and HP1protein to the E2F
promoters [21]. In 2003, Yang and coworkers had established the
interaction between the H3K9 methyl transferase enzyme ESET
(ERG-associated protein with SET domain) and the Sin3/HDAC
complex [12]. It was also recognized that histone and DNA
methylation cooperate to establish long-term states of transcrip-
tional regulation and the MeCP2 protein (methyl-CpG-binding
domain protein) associates with the H3K9-specific HKMT activity
[47]. The MeCP-2 protein itself is an important member of the
Sin3 corepressor complex [14]. Taken together it can be
speculated that ESET could be responsible for the H3K9Me3
activity observed at the HSPA8 and CRYZ promoters and in
concert with the MeCP2, the p53-Sin3B complex mediates the
repression of the aforementioned promoters. However the role of
other H3K9MTs like Suv39H1/2, G9a, GLP and Eu-HMTase
cannot be ruled out. Additionally different degrees of lysine
methylation (mono-, di- or trimethyl moieties) can have different
functional consequences [48] and hence need to be further
investigated along with an analysis of the interplay between H3K9
methylation and other repressive or activating lysine methylations
(H3K27 and H3K4 respectively) in the presence and absence of
genotoxic stress.
In conclusion our studies demonstrate that the transcriptional
control of HSPA8, MAD1 and CRYZ is dictated by p53 mediated
recruitment of hSin3B/HDAC1 co-repressor complex and is
modulated by context dependent epigenetic modifications. It is
worth noting that p53 regulatory responses are dependent on type
of cellular stress and can be cell-type specific. Although in our
present study we have used cell lines of varied origin and
demonstrated that p53-mediated repression of HSPA8, MAD1 and
CRYZ is conserved between different cellular backgrounds yet the
role of cell-type specific trans-acting factors in the fine tuning of
the expression of these promoters, under different cellular stresses
cannot be ruled out. Our findings here propose the existence of
pre-assembled p53-Sin3B co-repressor complex at the target
promoters which upon cellular stress direct chromatin remodeling
and downstream target gene repression. The present study
highlights for the first time the essential role of Sin3B as an
important associate of p53 in mediating the cellular responses to
stress and in the transcriptional repression of genes encoding for
heat shock proteins or proteins involved in regulation of cell cycle
and apoptosis.
Materials and Methods
Cell culture
Head and Neck squamous carcinoma cell line KB; Human
embryonic kidney cell line HEK293; Colon carcinoma cell line
HCT116; non-small cell lung carcinoma cell lines, A549 and
H1299; Osteosarcoma cell line, Saos2; and hepatoma cell line
Hep3B; were maintained in DMEM high glucose media
supplemented with 10% heat inactivated fetal bovine serum
(FBS) and 60 mg/ml penicillin and 50 mg/ml streptomycin. All
cells were grown at 37uCi n5 %C O 2 humidified atmosphere. All
the cell lines except HCT116 and H1299 were obtained from the
cell repository at NCCS, Pune. HCT116 and H1299 cells were a
kind gift from the laboratory of S. Das, National Institute of
Immunology, New Delhi.
Cell treatment/p53 induction
Subconfluent (50%–60%) cultures were incubated with Adria-
mycin (0.25–2 mg/ml; Sigma) for 16 hr at 37uCi n5 %C O 2
humidified atmosphere. The cells were harvested for i) Western
Blotting, ii) Co-immunoprecipitations, ii) Immuno-staining, iv)
Chromatin Immunoprecipitation and v) RNA isolation as
described below.
Western Blotting
To assess the protein levels, cells were harvested and lysed in
RIPA buffer (50 mM Tris-Cl, pH 8.0; 150 mM NaCl, 1% NP-40,
0.5% sodium deoxycholate, 2 mM EDTA, 1 mM PMSF, NaF
and protease inhibitor cocktail from Sigma Aldrich) for 45 min at
4uC. The soluble protein fraction was collected by centrifugation
at 12,000 rpm. Total protein was estimated using BCA protein
estimation kit (Bangalore Genei; India) and equal amount of
proteins (100 mg) were resolved on 8% SDS–polyacrylamide gels
and transferred onto immunoblot-PVDF membranes (Santacruz
Biotechnology, USA). Western blots were blocked in 3% Bovine
Serum Albumin (BSA). Blots were incubated with 1 mg/ml of 1:
1000 diluted antibody (anti-p53, sc-98; anti-Sin3B, sc-13145/sc-
768/sc-55516; anti-bactin, sc-47773) for 1.5 hr at room temper-
ature, followed by washing in PBS containing 0.5% Tween-20.
Thereafter the blot was incubated in peroxidase-conjugated
secondary antibody of 1:5000 dilution (Santacruz Biotechnology,
USA) and detected by using DAB (3,39-diaminobenzidine
tetrahydrochloride, Bangalore Genei; India) substrate or by
chemiluminescence detection (Santacruz Biotechnology, USA).
Immunoprecipitation
Subconfluent cultures of cells were harvested and lysed in NP-
40 buffer (20 mM Tris-HCl buffer pH-7.4, 100 mM NaCl,
0.5 mM EDTA, 0.5% NP-40) supplemented with protease
inhibitor cocktail (Sigma Aldrich). Total protein (2 mg) from each
sample was immunoprecipitated with 1 mg of desired antibody.
Each immunoprecipitate was washed thrice in NP-40 buffer,
fractionated on 8% SDS-PAGE and transferred overnight onto
Immuno-Blot PVDF membrane (Santacruz Biotechnology, USA)
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TM
IP/WB Optima E System (sc-45042) from Santa Cruz was used
for performing the reciprocal CoIP experiments that involved IP
with mouse anti-Sin3B (sc-13145) and detection by anti-p53 (sc-
98). IP/WB Optima E System is intended for use in such
homologous IP/WB applications and is optimized to detect the
desired Western blot probe antibody without detection of heavy
and light chains of the IP antibody.
Yeast two Hybrid assays
Yeast two hybrid tests were performed using the Matchmaker
Two Hybrid System 3 (Clontech, USA) according to the
manufacturer’s protocols. Yeast (Saccharomyces cerevisiae) strain
AH109 was used to determine protein-protein interactions. The
GAL4 DNA binding domain (BD) vector pGBKT7 and the
activation domain (AD) vector pGADT7 were used throughout.
Desired DNA fragments containing coding sequence of human
p53 (Gene ID: 7157) and human Sin3B (Gene ID: 23309) were
PCR amplified from human brain cDNA library (Clontech) using
gene-specific primers (Supplementary Table S1). Full length
human p53 was cloned in the pGADT7 vector (pGADT7-hp53).
Three overlapping fragments of human Sin3B (spanning the full
length coding region; Supplementary Figure S3) were cloned in
pGBKT7 vector: pGBKT7-Sin3B1–399 (N-terminal Sin3B amino
acids 1–399), pGBKT7-Sin3B193–468 (amino acids 193–468) and
pGBKT7-Sin3B442–1162 (C-terminal amino acids 442–1162). All
other truncated p53 and Sin3B constructs were derived from
pGADT7-hp53 and pGBKT7-Sin3B1–399 respectively.
pGBKT7-Sin3B and pGADT7-hp53 clones were co-trans-
formed in yeast strain AH109 and co-transformants were selected
using drop-out (DO) medium, lacking tryptophan and leucine (SD
LT). The selected co-transformants were replica plated on to
dropout medium lacking leucine, tryptophan, adenine, histidine
and containing Xgal (SD QDO-Xgal) and allowed to grow until
the colonies appeared. AH109 cotransformed with murine
pGBKT7-p53/pGADT7-T (supplied by Clontech) was used as
positive control, whereas yeast cotransformed with pGADT7/
pGBKT7 were used as negative control. b-galactosidase assay was
performed as per the manufacturer’s protocol.
Expression Analysis of Human p53 and Human Sin3B
Monolayer cells were washed twice with ice cold PBS and
trypsinized. The trypsinized cells were washed with ice cold wash
buffer (PBS +0.1% BSA). The cells were then fixed with 2%
Paraformaldehyde (PFA) at a density of 10
6 cells/100 ml and
stored overnight at 4uC. The cells were washed twice with ice cold
wash buffer to completely remove PFA. The cells were incubated
in permeabilization buffer (0.5% saponin +0.05% Triton X 100 in
PBS) for 10 min in ice and then washed twice with ice cold wash
buffer. The cells were then incubated with 1–2 mg of monoclonal
antibody (anti p53 or anti Sin3B) diluted in dilution buffer
(PBS+0.01% saponin +1%BSA +1% sodium azide) and incubated
at 4uC for one and half hours. The cells were washed twice with
ice cold wash buffer and then incubated with FITC conjugated
secondary antibody for 45 minutes in dark at 4uC. The cells were
washed twice with ice cold wash buffer and analyzed for
expression of hp53 or Sin3B on FACSCalibur and LSR II using
CellQuestPro and FlowJo Softwares (Becton Dickinson).
Chromatin Immunoprecipitation
Cultured cells were crosslinked using 1% formaldehyde, lysed,
sonicated and samples were immunoprecipitated, washed and
reverse crosslinked as described by Soutoglou and Talianidis in
2002 with several modifications [49]. Briefly, the crosslinked cells
were suspended in 0.1% SDS lysis buffer (50 mM Tris pH 8.0,
140 mM NaCl, 1 mM EDTA, 1% TritonX100, 0.1% Sodium
deoxycholate, 0.1% SDS, Protease inhibitors cocktail) and then
sonicated for 30 cycles of 30s pulse at maximum power using a
Bioruptor (Diagenode) to an average length of 200–500 bp of
DNA. After centrifugation, the samples were precleared with
Protein A-Agarose beads (preblocked with 1 mg/ml salmon sperm
DNA and 1 mg/ml of BSA). The precleared chromatin was
immunoprecipitated with 1–2 mg of antibodies, and the immune
complexes were collected by adsorption to Protein A-Agarose. The
beads were washed thrice with 0.1% SDS lysis buffer, twice each
with wash buffer A (50 mM TrisCl pH 8.0, 500 mM NaCl, 1 mM
EDTA, 1% TritonX 100, 0.1% Sodium deoxycholate, 0.1% SDS
and protease inhibitor cocktail), wash buffer B (20 mM TrisCl
pH 8.0, 250 mM LiCl, 1 mM EDTA, 0.5% NP-40, 0.5% Sodium
deoxycholate and protease inhibitor cocktail) and 16 TE. The
immunocomplexes were eluted with 1%SDS, 0.1 M NaHCO3 at
37uC for 30 min; decrosslinked by adding 200 mM NaCl and
incubated at 65uC for 6 hr. After successive treatments with 10 mg
of Rnase A and Proteinase K (20 mg/ml), the samples were
extracted with phenol-chloroform and precipitated with ethanol.
PCR of the target promoter were performed on immunoprecip-
itated chromatin using promoter specific primers (Supplementary
Table S2). ChIP DNA was detected by ethidium bromide staining
of PCR products after gel electrophoresis.
Total RNA isolation and semi-quantitative and
quantitative RT-PCR
Total RNA was extracted with RNeasy plus Mini kit (Qiagen,
USA). RNA (1 mg) was reverse transcribed with first strand cDNA
synthesis kit (Fermentas). Gene-specific primers designed across
the exon-exon boundary were used for RT-PCR (Supplementary
Table S3). Quantitative RT-PCR (qRT-PCR) was performed in
triplicates using SYBER green quantitative PCR kit (Eurogenetec,
Germany) and a 7300 detector (Applied Biosystems) under
conditions standardized for each primer set. PCR quantification
was done using the comparative Ct method (delta delta Ct
method). 18S ribosomal RNA gene was used as endogenous
control.
Statistical Analysis
All statistical analysis was performed using GraphPad Prism
version 5 (GraphPad Software Inc., San Diego, CA, USA). The
results of flow cytometry and qRT-PCR are presented as mean 6
SEM. Paired t-test was used for comparisons and calculating the
level of significance.
Supporting Information
Figure S1 IP-Western analysis of KB cell extract with
different antibodies specific for hSin3B. KB cell lysates
were immunoprecipitated with anti-p53 antibody (sc-98, Santa
Cruz Biotechnology, USA) followed by immunoblotting (IB) with
different antibodies specific for Sin3B (sc-13145, sc-55516, sc-768,
Santa Cruz Biotechnology) as indicated. Western analysis indicates
the consistent presence of Human Sin3B in p53 immune
complexes in KB cell extract.
(DOC)
Figure S2 Association of HDAC1 with Sin3B immune
complexes. (A) KB (p53
+/+) cell lysates were immunoprecipitat-
ed with anti-HDAC1 antibody (sc-8410, Santa Cruz Biotechnol-
ogy) followed by immunoblotting (IB) with antibodies specific for
Sin3B as indicated. Western analysis indicates the consistent
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H1299 (p53
2/2) cell lysates were immunoprecipitated with anti-
HDAC1 antibody or anti-Sin3B antibody as indicated followed by
immunoblotting (IB) with appropriate antibodies (Anti-Sin3B in
left panel and Anti-HDAC1 in the right panel). IP-Western
analysis indicates the presence of Human Sin3B-HDAC1 immune
complexes in a p53-independent manner.
(DOC)
Figure S3 Three overlapping fragments of human
Sin3B. Sin3B1–399 (N-terminal Sin3B amino acids 1–399);
Sin3B193–468 (amino acids 193–468) and Sin3B442–1162 (amino
acids 442–1162); spanning the full length coding region of human
Sin3B were cloned in yeast shuttle vector pGBKT7 vector.
(DOC)
Figure S4 Western blot analysis for p53 and Sin3B
expression in AH109 co-transformants. (A) Immunoblotting
to confirm the expression of hp53 in cotransformants in yeast cells.
Western analysis of hp53 cotransformed with different overlapping
fragments of Sin3B in AH109 cell lysates as indicated above each
lane i.e. pGBKT7-Sin3B1–399 X pGADT7-hp53, pGBKT7-
Sin3B193–468 X pGADT7-hp53, pGBKT7-Sin3B442–1162 X
pGADT7-hp53 and pGBKT7 X pGADT7-hp53. (B) Western
blot to check the expression of the three Sin3B-pGBKT7 clones
expressed in AH109 cells. Western analysis of Sin3B1–399 (Panel i),
Sin3B193–468 (Panel ii), and Sin3B442–1162 (Panel iii) in different
cotransformants as indicated i.e. pGBKT7-Sin3B X pGADT7-
hp53 or pGBKT7-Sin3B X pGADT7.
(DOC)
Figure S5 Yeast two Hybrid analysis for the interaction
of hSin3B with mouse p53 (mp53 lacking the N-terminal
72 amino acids). Yeast AH109 cells were co-transformed with
(i) pGBK T7-mp53 (GBK-p53) and pGAD T7-Sin3B1–399 (NTS)
(ii) GBK vector (GBK) and NTS (iii) GBK-p53 and T antigen
(GADT) as indicated on the plates. The protein-protein interac-
tions were checked by growing the co-transformants on selective
SD QDO medium (Quadruple drop-out medium lacking leucine,
tryptophan, adenine and histidine). Positive interaction was
observed only between pGBK-p53 and GADT antigen as
indicated by the black arrow but no interaction was observed
between Sin3B and N-terminal deleted mouse p53 as no growth
was observed on the SD QDO medium (patches 1–16).
(DOC)
Figure S6 Adriamycin induces a predominant S/G2 cell
cycle arrest in p53 null cell lines. Saos2, H1299 and Hep3B
cells were treated with 1.0 mg/ml Adriamycin for 16 hours
followed by propidium iodide staining and cell cycle analysis.
Adriamycin treatment induced a predominant S/G2 cell cycle
arrest in the p53
2/2 cells.
(DOC)
Figure S7 Levels of p21 are up-regulated in KB and
HCT116 cells in response to Adriamycin treatment.
qRT-PCR was performed to calculate fold activation of p21
transcript. A 2960.6124 fold transactivation in KB cells and
15.4660.5357 fold activation in HCT116 cells were observed for
p21.
(DOC)
Table S1 Primer Sequences for Cloning Sin3B and p53
in yeast shuttle vectors pGBKT7 and pGADT7.
(DOC)
Table S2 Primers for Chromatin immunoprecipitation.
(DOC)
Table S3 Primers for semi-quantitative and Real time
PCR.
(DOC)
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